Chief Medical Officer (Australia)

Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023

Retrieved on: 
Tuesday, October 31, 2023
Type, FDA, BMT, Inflammation, Mesoblast, Blood, Growth, MESO, Appendix, Chief Medical Officer (Australia), Executive, Non-executive director, MSB, Back pain, Transplant, Dietary supplement, Pharmaceutical industry, Bank

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the first quarter ended September 30, 2023.

Key Points: 
  • NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the first quarter ended September 30, 2023.
  • In this regard, we are working on corporate initiatives to strengthen our balance sheet, including royalty monetization and strategic partnerships to both access existing commercial distribution channels and supplement costs of development.
  • Cash balance at the end of the quarter was US$53.2 million, with net operating cash spend of US$14.2 million.
  • Revenue from royalties on sales of TEMCELL® HS Inj.2 sold in Japan by our licensee for the quarter were US$1.6 million.

SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer

Retrieved on: 
Wednesday, September 6, 2023
Contact tracing, University, Internal medicine, Public, EVP, COVID-19, Smallpox, Infection, COVID, CMO, Harvard College, CDC, MPOX, SIGA Technologies, Interdisciplinary Association for Population Health Science, Risk, Chief Medical Officer (Australia), Weill Cornell Medicine, Safety, Management, Pharmaceutical industry, Vaccine

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO).

Key Points: 
  • NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer (CMO).
  • He will also continue to serve as a director of the SIGA Board of Directors.
  • “In his new additional role as EVP and Chief Medical Officer, he will be positioned to apply even more of his outstanding insight and experience to support our advocacy efforts.”
    As EVP and CMO, Dr. Varma will lead medical affairs.
  • SIGA plays a central role in helping countries around the world understand and respond to potential outbreaks of smallpox, MPOX and other orthopox viruses,” said Dr. Varma.

Bloom Health Centers expands its top-tier mental healthcare services to Winchester with the opening of its newest location

Retrieved on: 
Monday, June 19, 2023
Insurance, Swansea University Medical School, TMS, West Midlands CARE Team, Quality of life, WINCHESTER, Multimedia, Chief Medical Officer (Australia), Hospital, Patient, Mental, Growth, Esketamine, Mental health, Feinberg School of Medicine, Mid-Atlantic (United States), Psychiatry, Nursing, Bloom

The expansion strategy has included identifying geographic areas with unserved mental health services and finding ways to get those individuals better access to care.

Key Points: 
  • The expansion strategy has included identifying geographic areas with unserved mental health services and finding ways to get those individuals better access to care.
  • I am looking forward to leading our team of mental health experts to support the wellness needs of Winchester and the surrounding communities."
  • With this new space in Winchester and expanded service area, Bloom can reach a larger audience with its personalized mental health care services.
  • To find the Bloom Health Center location nearest to you and request an appointment online, please visit www.bloomhealthcenters.com .

Curium Receives Positive CHMP Opinion of PYLCLARI® for Primary Staging of Patients With High-Risk PCa Prior to Initial Curative Therapy and to Localize Recurrence of PCa in Patients With a Suspected Recurrence Based on Increasing Serum Prostate-Specific A

Retrieved on: 
Friday, May 26, 2023
Curium, CONDOR, Civil service commission, Prostate cancer, PSMA, European Medicines Agency, Committee for Medicinal Products for Human Use, Cancer, PET, Marketing, Committee, EMA, Nuclear medicine, Food and Drug Administration, Şakir, MD, Patient, Master of Science, Chief Medical Officer (Australia), INN, PCA, Phase, FDA, Recurrence, PSA, Food, European Commission, CHMP, Medical imaging, Piflufolastat F-18

Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented, “This positive CHMP opinion for PYLCLARI® is an important step forward in our goal of redefining the experience of cancer through our trusted legacy in nuclear medicine.

Key Points: 
  • Sakir Mutevelic, MD, MSc, Chief Medical Officer at Curium commented, “This positive CHMP opinion for PYLCLARI® is an important step forward in our goal of redefining the experience of cancer through our trusted legacy in nuclear medicine.
  • Upon its approval, PYLCLARI® will become available across Europe to help patients along their prostate cancer journey.
  • We are very excited to bring PYLCLARI® to the market and contribute to improving the set of diagnostic tools available to better diagnose and monitor prostate cancer.
  • The CHMP’s positive opinion on PYLCLARI® will be referred to the European Commission, which will deliver a final decision in approximately two months.